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Abstract | Dementia is a frequent problem encountered in advanced stages of Parkinson disease 
(PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment 
in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that 
MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of 
cognition — or even reversal to normal cognition — is not uncommon. In addition to limbic and 
cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive 
decline in PD, and a variety of biomarker studies, some using novel structural and functional 
imaging techniques, have documented in vivo brain changes associated with cognitive 
impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-
β42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia 
in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established 
risk factor for AD, GBA mutations and SCNA mutations and triplications are associated with 
cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive 
enhancing medications have some effect in PD dementia, but no convincing evidence that 
progression from MCI to dementia can be delayed or prevented is available, although cognitive 
training has shown promising results. 
 
Introduction 
Parkinson disease (PD) is one of the most common age-related brain disorders. PD is defined primarily 
as a movement disorder, with the typical symptoms being resting tremor, rigidity, bradykinesia and 
postural instability, and is pathologically characterized by degeneration of nigrostriatal dopaminergic 
neurons and the presence of Lewy bodies (misfolded α-synuclein) in the surviving neurons. In addition 
to the defining dopamine-related motor symptoms, however, PD is increasingly recognized as a 
heterogeneous multisystem disorder involving other neurotransmitter systems, such as the 
serotonergic, noradrenergic and cholinergic circuits. Thus, a wide variety of nonmotor symptoms 
(NMS) linked with these neurotransmitters are commonly observed in patients with PD. In light of this 
variability, subtyping of PD has been proposed, including a subtype based on time of onset and ongoing 
rate of cognitive decline1.  
Cognitive decline is among the most common and important NMS, and in this article we review 
the current status of knowledge regarding cognitive impairment in PD. Robust evidence indicates that 
in comparison with age-matched groups without PD, people with PD exhibit more rapid decline in a 
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number of cognitive domains — in particular, executive, attentional and visuospatial domains, but also 
memory. The full spectrum of cognitive abilities can be observed in PD, from normal cognition, through 
early mild subjective and objective decline (mild cognitive impairment (MCI)), to mild, moderate and 
even severe PD dementia (PDD). Studies from the 1990s onwards convincingly demonstrated a much 
higher cumulative risk of dementia in people with PD than in the general population, and systematic 
reviews showed that the point prevalence of dementia was 25–30%. Several long-term longitudinal 
studies have indicated that the majority of patients with PD will develop dementia if they survive for 
more than 10 years after diagnosis. On the basis of numerous, varied studies, we now know that 
dementia in PD has important adverse implications for functioning, quality of life, caregiver burden, 
and health-related costs2.  
The timing, profile and rate of cognitive decline vary widely among individuals with PD, so 
identifying and predicting future cognitive decline in this population is crucial for researchers and 
clinicians alike. Identification of clinical and biological markers that can predict which patients are at 
increased risk of early and rapid cognitive decline is important for communicating the prognosis and 
managing patients clinically and, thus, is a focus of this article. Established demographic and clinical 
risk factors include increasing age and more severe parkinsonism, in particular, non-tremor features2. 
Here, we focus on cognitive and biomarker features as potential predictors of cognitive decline in PD. 
 
Cognitive syndromes in PD  
 
Subjective cognitive decline 
In recent years, interest has focused on subjective cognitive decline (SCD), in which cognitive 
impairments are noted by the patient, family members or health personnel, but cognitive test 
performance is in the normal range. In the general population, SCD is associated with an increased risk 
of future cognitive decline, that is, progression to MCI or dementia, including Alzheimer disease (AD). 
Relatively little is known about SCD in PD, and there are no established criteria for this syndrome. No 
reliable method of capturing SCD in PD yet exists, possibly owing partly to the confounding effects of 
motor symptoms and NMS. Nevertheless, SCD has been reported in patients with PD, and might be a 
harbinger of further cognitive decline in this population14. 
 
MCI and the risk of PD dementia 
The two most common cognitive syndromes in patients with PD, PDD and PD-MCI, were operationally 
defined in diagnostic and assessment guidelines from the International Parkinson and Movement 
Disorder Society (MDS)3,4. In PDD, but not in PD-MCI, the cognitive deficits are severe enough to impair 
daily life (for example, social and occupational functioning, and personal care), independently of the 
impairment ascribable to motor or autonomic symptoms.  
Among PD patients without dementia, approximately 25–30% have MCI, which is evident at 
the time of diagnosis in 10–20% of patients2. Presence of MCI is associated with a shorter time to 
progression to a dementia diagnosis, although considerable variability is observed, with some patients 
remaining stable and some even reverting to normal cognition. For example, in one study of patients 
with early PD5, over 20% of those with MCI reverted to normal cognition after 1 year, although 
persistent MCI was associated with a much lower remission rate.  
Early studies indicated that the mean time to dementia after PD diagnosis was approximately 
10 years. This figure is supported by more recent studies, including some that monitored patients from 
the time of PD diagnosis (TABLE 1), which reported dementia prevalence of 15–20% after 5 years and 
46% at 10 years6. However, lower dementia rates (5% after 4 years) have been reported elsewhere7. 
One study that selected only PD patients with normal cognition reported that nearly 50% had 
developed cognitive decline after 6 years8. Some studies9 suggest that cortical posterior cognitive 
deficits (that is, memory and language impairment), but not frontally based dysfunction, indicate a 
higher risk of dementia, leading to the ‘dual syndrome hypothesis’ of cognition in PD. Discrepancies 
between studies are likely to be attributable to a variety of factors, including differences in case 
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selection, whether duration was measured from onset of symptoms or diagnosis, use of different 
criteria for PD-MCI and PDD, and loss to follow-up.  
 
Clinical challenges  
Cognitive decline in PD is a continuous process affecting nearly all patients over time, and the 
demarcations between the four cognitive groups — cognitively normal, SCD, PD-MCI and PDD — are 
not strict. The distribution of patients in these four groups vary markedly among different studies, 
depending on factors including the case selection procedures, the criteria applied, the study design 
(cross-sectional or longitudinal), and the cognitive measurement procedures utilized. A recent study, 
which attempted to define the optimal criteria for PD-MCI, found that impairment (>1.5 SD below the 
normative mean) on two tests within the same cognitive domain — rather than across different 
domains — was the best predictor of progression to dementia during the next 4 years15. As highlighted 
above, the separation between MCI and dementia hinges on whether the functional impact of 
cognitive impairment is ‘severe enough to impair daily life’, a criterion that is difficult to operationalize 
and requires an element of clinical judgement.  
Another clinical challenge is the distinction between PDD and dementia with Lewy bodies 
(DLB), owing to their clinical and pathological overlap. The ‘1-year rule’, in which PDD is defined as 
dementia that occurs at least 1 year after onset of PD motor symptoms, whereas dementia occurring 
prior to, simultaneously with, or within the first year of onset of parkinsonism is classified as DLB, is 
often difficult to apply, as a substantial proportion of patients lie within the grey zone, and 
categorization is usually performed retrospectively. In addition, prodromal PD and DLB symptoms 
overlap; for example, REM sleep behaviour disorder (RBD) can evolve into either PD or DLB. Recent 
evidence indicates that cognitive impairment can be present in prodromal PD, further blurring the 
distinction between PD and DLB16. The recently revised MDS clinical diagnostic criteria for PD propose 
that PD can be diagnosed regardless of when dementia occurs in relation to parkinsonism onset, and 
in cases where parkinsonism subsequently develops in a patient with dementia, the diagnosis ‘PD (DLB 
subtype)’ is recommended17. The relationship between PD and DLB requires further exploration. For 
example, recent findings indicate several nonmotor subtypes of PD, including cognitive and non-
cognitive forms, which can occur in early untreated motor disease in late-onset PD, as well as in early-
onset PD18,19. From a practical perspective, an algorithm in which premotor NMS such as RBD are 
channelled towards potential transformation to motor PD, including cognitive phenotypes, has been 
proposed19. 
 
Visual hallucinations and dementia risk 
Several longitudinal studies have identified visual hallucinations and illusions as risk factors for 
cognitive decline and dementia in PD, with the time frame depending on the study design. In one study, 
a history of visual hallucinations at baseline was found to increase the risk of dementia at 8 years (OR 
3.1, 95% CI 1.6–6.2)20, and another group found that baseline visual hallucinations (OR 10.2, 90% CI 
2.4–44.0) or illusions (OR 8.2, 90% CI 2.4-28.4) increased the risk of dementia at 4–5 years21. The 
association between visual hallucinations and dementia that has been observed in prospective studies 
might reflect progression of cognitive dysfunction, which seems to be present before or coincident 
with hallucination onset22. 
 
Mechanisms 
A variety of mechanisms, in addition to the classic nigrostriatal α-synuclein misfolding and 
dopaminergic neuronal loss, contribute to the brain changes associated with PD (BOX 1). PD is now 
recognized to involve multisystem, multipeptide neurodegeneration, with non-dopaminergic 
degeneration having a crucial role. 
Compared with the motor symptoms, little is known about the mechanisms underlying cognitive 
decline in PD, and several key questions remain unresolved. First, is cognitive decline merely a result 
of more severe and widespread involvement of primary PD neuropathophysiology? Second, are some 
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of the PD-related mechanisms particularly relevant for cognitive decline? Last, is cognitive impairment 
related to regional involvement or specific mechanisms? 
Information on the mechanisms underlying cognitive decline in PD has come from a variety of 
sources. In addition to post-mortem studies, in vivo studies, including clinicopathological studies and 
biomarker studies involving electrophysiological, imaging, electrophysiology and biofluid analyses, and 
genetic studies, have all contributed to an increased understanding. However, animal models for PD-
related cognitive deficits have been difficult to develop.  
 
Evidence from pathological studies 
The pathological contributions to dementia in PD have been studied in some detail, and have been 
reviewed in detail elsewhere23. Good evidence from post-mortem studies indicates that limbic and 
cortical Lewy body pathology is the main pathological correlate of dementia in PD. In most cases, α-
synuclein pathology seems to spread from sites in the lower brainstem or olfactory bulb — or even 
extracranially from the gut or other areas innervated by the vagus nucleus1 — to the midbrain, 
forebrain and limbic structures and, finally, neocortical regions24. 
In addition, there is strong evidence that the extent of amyloid plaque pathology is a 
significantcontributor to dementia in in up to one-third of PD patients, whereas the role of tau-related 
pathology is less clear. Importantly, the three proteinopathies in combination seem to have an additive 
effect over and above the effect of any single pathology25,26. This finding is in line with basic 
neuroscience studies, which show an interaction between the processing of these three proteins. For 
example, transgenic mice with double pathology (that is, overexpression of α-synuclein on a 
background of amyloid-β (Aβ) or tau pathology) show more severe Lewy body pathology than mice 
overexpressing α-synuclein pathology only27. Clinically, these effects manifest as earlier and more rapid 
cognitive decline in patients with combined Lewy body and amyloid pathology28. The roles of other 
pathologies, including cerebrovascular disease, hippocampal sclerosis and cerebral amyloid 
angiopathy, are also beginning to be explored. 
 
Synaptic pathology and cognition 
The structural pathologies described above are relevant, but only partially explain the variance in 
cognitive decline in patients with PD. A better understanding of the disease substrate is needed for 
targeted drug discovery and to enable better monitoring of disease progression. Changes in synaptic 
function followed by synaptic loss are likely to be early and key events in neurodegenerative diseases: 
in AD, loss of synapses was found to be more robustly correlated with cognitive decline than was 
morphological pathology29. Less is known regarding the role of synaptic dysfunction in cognition in PD, 
but synaptic alterations have been demonstrated (reviewed elsewhere30). 
In PD, mounting evidence indicates that the initial damage in dopaminergic nigral neurons 
occurs at the synapse, with subsequent retrograde axonal damage and, finally, somatic degeneration, 
leading to the typical motor symptoms of PD (reviewed elsewhere31). Similar mechanisms might 
underlie limbic and cortical involvement in PD. These events probably involve α-synuclein, which is 
mainly located synaptically and regulates synaptic homeostasis, vesicles and neurotransmitter release, 
and initially aggregates at the synaptic terminal during PD pathogenesis 32. Of note, several other 
proteins implicated in PD — in particular, PINK1, Parkin, leucine-rich repeat serine/threonine-protein 
kinase 2 (LRRK2) and DJ1 — are also involved in synaptic regulation. We have found that reduced 
neocortical level of ZnT3, a marker of synaptic plasticity, and two key synaptic proteins, neurogranin 
and SNAP2533,34, are associated with cognition in PD. These findings suggest that cortical synaptic 
changes lead to cognitive decline in PD, consistent with imaging findings (see below), and preliminary 
work indicates that synaptic changes are also reflected in the cerebrospinal fluid (CSF). Neurogranin 
levels were found to be increased in the CSF in AD35, probably due to increased intracellular 
sequestration, and similar findings have been reported — and linked with cognitive decline — in PD36. 
Thus, CSF levels of synaptic proteins are potential biomarkers of future cognitive decline.  
 
Neurotransmitters 
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Convincing evidence is available that mesolimbic and mesocortical dopaminergic activity is associated 
with cognitive functioning. The association between dopaminergic drugs and cognition is complex, 
however, and antiparkinson drugs can improve, worsen or have no influence on cognition37. In 
addition, a number of non-dopaminergic transmitter systems are affected in PD, and are likely to 
contribute to cognitive impairment23. For example, good evidence from post-mortem and imaging 
studies indicates that the cholinergic system is affected relatively early in PD and contributes to the 
cognitive decline. Interestingly, whereas Lewy body and amyloid plaque pathologies were associated 
with earlier onset of dementia, cholinergic deficits were more pronounced in individuals with dementia 
occurring later in the disease course28,38. These observations provide a rationale for the positive effects 
of cholinesterase inhibitors in PD (see treatment section below), as well as the worsening cognition 
associated with the use of medications with anticholinergic activity39.  
Non-dopaminergic monoaminergic nuclei such as the noradrenergic locus coeruleus and the 
serotonergic raphe nuclei, with their long and widespread mesocortical connections, may affect 
cognition due to their influence on the activity of synaptic networks. This hypothesis was supported in 
a recent study, which showed that the ability of atomoxetine-mediated noradrenergic or citalopram-
mediated serotonergic reuptake inhibition to improve response inhibition — a frontal executive task 
relevant to impulsivity — in patients with PD could be predicted by differences in brain activation, as 
measured by functional imaging40. In the serotonin system, several receptors are associated with 
cognition, including the 5-HT1B receptor, which was found to be downregulated in early PD in a recent 
PET study using a novel ligand, but was not associated with executive or attentional functioning41. 
Striatal GABAergic neurons express adenosine A2A receptors, which have become a drug 
target to improve motor functioning in PD. These receptors are also located in the thalamus and 
neocortex, and some evidence indicates that increased receptor activity is associated with worsening 
cognition. Adenosine A2A antagonists may increase dopamine activity in the prefrontal cortex, and 
preliminary evidence suggests that they can improve cognition, in particular working memory, in 
PD42,43. 
 
Mitochondrial activity 
Mitochondrial dysfunction occurs in PD, but little is known regarding its potential role in cognitive 
decline. However, mitochondrial pathology seems to contribute to cognitive decline in AD, and a 
recent post-mortem study showed that deficiency in mitochondrial complex 1 activity and reduced 
mitochondrial DNA levels in the prefrontal cortex were more pronounced in PDD than in PD without 
dementia44. Mitochondrial activity is particularly high at the synapse, and is crucial to synaptic activity. 
A relationship between α-synuclein and mitochondrial activities at the level of synapses has been 
demonstrated, but their causal relationship needs to be further explored. Therapeutic approaches 
targeting mitochondrial activity, including complex 1 deficiency, are being developed, and 
manipulation of mitochondrial retrograde signalling has shown promising results in animal studies45. 
The role of mitochondrial dysfunction in cognitive decline in PD needs to be further explored. 
 
Inflammation and neurotrophic factors 
Neuroinflammation is relevant for both AD and PD, and might have important implications for 
cognitive decline in PD46, with a potential for novel treatment targets. Increased microglial activation 
is thought to lead to cell death in AD and PDD47, and inflammation markers represent possible 
prognostic biomarkers. Interestingly, CSF levels of cytokines are found to be associated with cognitive 
impairment in PD48 and, thus, represent possible biomarkers (see below). 
Findings from many different sources convincingly demonstrate a link between diabetes, 
insulin resistance and PD, possibly via mechanisms involving neuroinflammation and mitochondrial 
dysfunction49. A recent imaging study in a cohort of 36 patients, 12 of whom had diabetes, reported 
an association between diabetes, grey matter loss and cognitive impairment in PD50, indicating a 
possible role for antidiabetic drugs in the treatment or prevention of cognitive decline in PD, as has 
been suggested in AD. 
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Neurotrophic factors are crucial for neuronal plasticity and, thus, learning and other cognitive 
functions. A longitudinal study showed that cognitive impairment in PD was associated with reduced 
levels of growth factors, such as brain-derived neurotrophic factor and epidermal growth factor, in 
CSF51 and plasma52. 
 
Summary  
In addition to α-synuclein, tau and amyloid pathologies, a number of other mechanisms, including 
different neurotransmitter systems, early synaptic changes, inflammation, and mitochondrial 
dysfunction, are likely to contribute to cognitive decline in PD. The roles of these as well as other 
potentially relevant mechanisms for cognitive impairment, such as the unfolded protein response53, 
the ubiquitin–proteasome system54, and increased neurogenesis (for example, in response to 
neurotrophic factors)55, need to be explored further (see Management section below).  
 
Genetic contributions 
The link between risk genes for cognitive impairment and decline in PD has been the subject of several 
detailed reviews2,23,56. BOX 2 provides a summary of genes examined to date, and the discussion below 
focuses on those with the largest bodies of evidence. 
Genetic variants that cause monogenic forms of PD have been extensively investigated with 
respect to their effects on the clinical presentation of PD, including cognition and susceptibility to 
dementia. The LRRK2 Gly2019Ser substitution is the most commonly studied mutation, and has been 
shown in the majority of studies to either have no effect on cognition or to be protective57–65. However, 
the sample sizes of the studies were restricted by the rarity of LRRK2 mutations, so an association with 
cognitive impairment cannot be ruled out. Moreover, limited longitudinal follow-up, along with 
assessment tools that lack the sensitivity to detect subtle changes, might mask true associations. α-
Synuclein gene (SNCA) mutations are another major cause of autosomal dominant PD and, in contrast 
to LRRK2 mutations, most seem to have deleterious effects on cognition, with the exception of 
duplications, which produce a clinical presentation similar to sporadic PD66–69. 
Polymorphisms in SNCA also confer a risk of sporadic PD, but examination of one risk variant 
(rs356219) in a large study failed to find any evidence of a relationship with cognition70. However, the 
recent identification of a haplotype in intron 4 of the gene and its association with PDD raises the 
possibility that SNCA-related mechanisms are associated with cognition in sporadic PD, warranting 
additional studies in longitudinally assessed cohorts71. 
Most other research in sporadic PD has largely focused on four candidate genes: 
glucosylceramidase (GBA), microtubule-associated protein tau (MAPT), apolipoprotein E (APOE) and 
catechol-O-methyltransferase (COMT). Of these, GBA has the strongest evidence base for association 
with cognitive measures: heterozygous mutations in this gene have been reliably shown to increase 
the risk of dementia72–76 and less severe impairments in frontal cognitive domains77. GBA is a highly 
polymorphic gene, and two large independent studies found that the type of mutation modulates the 
relationship with cognitive decline, furthering the possibility for disease subtyping on the basis of 
genetic status78,79. 
The strong association between APOE and AD has led to extensive investigation of the 
relationship between AD risk alleles and cognition in PD. Tentative conclusions were drawn from a 
large meta-analysis showing a relationship with dementia80, and some70,81,82 — but not all83,84 — 
subsequent studies have reported effects on cognition, as measured by a variety of neuropsychological 
tests. These findings point to potential genetic overlap between AD and PD, a position strengthened 
by recent research leveraging PD genome-wide association study data, which found evidence of 
genetic pleiotropy at the MAPT locus85. Whether these findings provide a mechanistic explanation 
specifically for cognitive impairment in PD remains to be fully established. 
Regional and cognitive domain-specific alterations in cortical activation associated with MAPT, 
APOE and COMT variants have been reported in two neuroimaging studies86,87. These findings 
complement those from neuropsychological studies, and might also go some way towards explaining 
the inconsistent results. In particular, although neuropsychological associations may not always be 
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detected owing to low statistical power or lack of sensitivity of the measures used, evidence is 
accumulating that genetic variation drives mechanistic alterations that are consistent with different 
patterns of cognitive deficits. These findings warrant clinical studies with larger sample sizes, 
conducted with cognitive batteries specific to the neural correlates of the genes of interest. 
Despite some compelling findings, experiments designed to examine the effects of single genes 
can only capture a small proportion of the variance of complex traits such as cognition. Genome-wide 
association studies go some way towards addressing this issue by simultaneously genotyping markers 
across the genome. One such study conducted in PD cognition found no genome-wide significant hits 
but, with only 443 cases, was underpowered88. The application of genome-wide methods in other 
diseases across neurology and psychiatry has generated promising findings85,89, but much larger data 
sets are needed in PD. The availability of such samples — and, consequently, the potential to conduct 
more powerful genetic analyses — is increasing. 
 
Biomarkers of cognitive decline in PD 
Cerebrospinal fluid biomarkers 
The variety of CSF-based markers in PD, and the biological factors that influence their levels in the CSF, 
was recently reviewed105. The most commonly studied markers have been the AD markers Aβ42 (a 
marker of Aβ pathology), total tau (t-tau, a marker of neurodegeneration) and phosphorylated tau (p-
tau, a marker of tau pathology), and the PD marker α-synuclein. In a comprehensive review of 
biomarkers and cognition in PD, Lin and Wu106 identified 18 CSF studies. The most consistent finding 
was an association between reduced CSF Aβ42 levels and cognitive impairment, which was reported in 
14 of 15 studies. By contrast, findings for t-tau and p-tau were inconsistent, with some studies 
reporting an association between increased CSF levels and cognitive impairment, but most reporting 
no associations. Subsequently, several more studies were published, including longitudinal studies 
reporting an association between CSF markers and future cognitive decline — a particularly relevant 
question for clinicians. In AD, CSF markers can accurately predict which patients with MCI will develop 
AD dementia in the near future, and CSF markers to predict accelerated cognitive decline in PD are an 
important priority. Two cross-sectional studies reported an association between low CSF Aβ42 levels 
and cognitive impairment in PD107,108. In addition, four longitudinal studies reported that reduced Aβ42 
predicted more rapid cognitive decline109–112, confirming previous findings113–115 (TABLE 2). DeNoPa, a 
multimodal biomarker study in de novo PD116, found no link between PD progression and CSF markers, 
but the results could have been confounded by the low number of participants agreeing to serial CSF 
sampling, variations in CSF sample preparation, and the demographics of the cohort. 
Several studies of CSF levels of total α-synuclein have been published. Most reported low 
values in PD, as confirmed by a recent meta-analysis118, but the association with cognition continues 
to be inconsistent, with both low 107 and high values110,117 found to be associated with cognitive decline 
in different studies. The discrepant findings might be explained by differences in disease stage. CSF α-
synuclein levels may increase with disease stage, and the association between high levels and cognitive 
impairment was found in more advanced disease but not early disease stages. In one study of CSF 
biomarker change with time, Hall et al.119 found that levels of t-tau, p-tau, total α-synuclein, 
neurofilament and YKL-40 (a marker of inflammation), but not Aβ42, increased over a 2-year period and 
were associated with worsening cognition, and the increase was particularly marked in patients with 
longer disease duration. These findings are consistent with reports that α-synuclein levels increase 
with more severe neurodegeneration. However, the DeNoPa study reported no change in α-synuclein 
or other CSF markers during a 24-month study period116. In addition to total α-synuclein, post-
translationally modified forms of α-synuclein, including phosphorylated, nitrated and ubiquitinated 
forms, as well as oligomers, have been identified, and show some promise as markers of disease 
progression in PD120–122, but further research is needed to confirm their diagnostic and prognostic 
utility as markers for cognitive impairment in PD. 
 
Neuroimaging 
Over the past decade, structural, functional and molecular neuroimaging techniques such as MRI123  
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and PET124–126 have considerably advanced our understanding of the complex mechanisms underlying 
the development of cognitive impairment in PD123,126. Two large, ongoing 5-year observational 
biomarker studies, PPMI and COPPADIS, are using a range of imaging assessments, and are expected 
to yield important information on the utility of MRI to detect brain pathology in PD patients with 
cognitive impairment127. In such patients, PET imaging has provided in vivo evidence for the interplay 
between several pathological processes, including degeneration of subcortical cholinergic and 
dopaminergic projections, microglial activation, and neocortical pathology associated with misfolded 
protein deposition or vascular pathology47,124,128. Also, functional polymorphisms in the COMT gene, 
which influence dopamine storage, might contribute to cognitive deficits in PD129.  
 
MRI measures of cortical and subcortical volume loss. Structural MRI can localize differences in 
regional cortical and subcortical tissue volume between groups of individuals. In PD patients without 
a formal diagnosis of PD-MCI or PDD, loss of tissue volume in frontal and parietal cortices has been 
associated with worse performance in decision-making, facial expression recognition, visual memory 
and executive function130–132. Studies in patients with PD-MCI have demonstrated a pattern of cortical 
volume loss in posterior, parietal and frontal cortices, and atrophy in the hippocampus, that correlates 
with memory deficits133–135. Longitudinal assessments of cortical thickness and subcortical volumes in 
patients with PD-MCI have indicated progression of cortical thinning in temporal, occipital, parietal 
and frontal cortices, and further loss of hippocampal volume that is associated with cognitive 
decline134,136. Retrospective analysis of structural MRI scans has demonstrated that in PD patients 
without cognitive impairment, this technique can predict conversion to PD-MCI status at 6 months on 
the basis of baseline hippocampal atrophy137, at 18 months on the basis of baseline temporal cortex 
thinning134, and at 2 years on the basis of baseline prefrontal thinning, and insular and caudate volume 
loss138. At the time when a PDD diagnosis is established, the pattern of cortical thinning becomes more 
severe in parietal, occipital, temporal and frontal cortices, and the volume loss in the hippocampus is 
substantial, including atrophy of parahippocampus, insula and cingulate gyrus that are associated with 
further decline of cognitive functions139–142. The pattern of cortical thinning has been also suggested to 
differentiate PDD, which shows a predominant frontal cortex thinning, from DLB, which shows a 
predominant parietal and occipital cortices thinning143. 
 
MRI-based structural and functional connectivity. Diffusion tensor imaging measures the magnitude 
(mean diffusivity) and direction (fractional anisotropy) of water molecule flow in brain tissue. 
Neurodegenerative disorders are characterized by damage to white matter tracts (structural 
connectivity) that results in increased mean diffusivity and decreased fractional anisotropy. In PD 
patients without a formal diagnosis of PD-MCI or PDD, increased mean diffusivity in the hippocampus, 
and frontal and parietal white matter tracts is associated with worse performance in terms of verbal 
and visuospatial memory, semantic fluency and other executive functions132,144–146. Also, decreased 
hippocampal fractional anisotropy correlates with measures of global cognitive decline146. 
Resting state functional MRI (fMRI) measures blood-oxygen-level dependent (BOLD) signal in 
the brain without an externally prompted task, and is useful to explore the functional organization of 
networks (functional connectivity) in the human brain. PD patients without a formal diagnosis of PD-
MCI or PDD exhibited progressive loss of resting state functional connectivity over a period of 3 years 
in multiple brain regions, especially the posterior parts of the brain, which correlated with decreasing 
cognitive performance147. Studies have demonstrated that cognitive decline in PDD is associated with 
disruption of corticostriatal and frontal cortex functional connectivity148,149. As seen with the pattern 
of cortical thinning on structural MRI, the pattern of functional connectivity disruption can 
differentiate PDD, which is characterized by predominant frontal cortex disruption, from DLB, which is 
characterized by predominant disruption of parietal and occipital cortices143. Further studies are 
needed to replicate these findings, and specifically to pinpoint the structural and functional brain 
networks that underlie cognitive decline in patients with PD.  
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Perfusion imaging. Arterial spin labelling (ASL) is an MRI-based technique that allows quantification of 
altered cerebral blood flow. ASL studies have demonstrated patterns of hypoperfusion in patients with 
PDD compared with cognitively normal PD patients150. The pattern of brain hypoperfusion in PDD 
largely overlaps with the hypoperfusion observed in the posterior cingulate gyrus, precuneus and 
occipital regions in patients with AD, but differs in the temporal lobes (AD < PDD) and right frontal 
cortex (PDD < AD)151. ASL is a promising technique that merits additional study in patients with PD and 
cognitive impairment. 
 
Dopaminergic molecular imaging. Studies involving dopamine decarboxylase and vesicular 
monoamine transporter 2 PET imaging have demonstrated decline in regional mesolimbic and 
mesocortical monoaminergic capacity in patients with PDD152,153. These patients show only subtle loss 
of monoaminergic capacity in the anterior cingulate, ventral striatum and caudate, which can be 
detected at a single-voxel level152. Visual or semi-quantitative assessment of dopamine transporters 
by PET or single-photon emission CT (SPECT) imaging reveals nigrostriatal degeneration in patients 
with PDD, and reduced caudate dopamine transporter uptake has been associated with impairment of 
executive functions154,155. However, dopaminergic molecular imaging can detect only subtle 
differences between PDD and PD, and no differences between PDD and DLB have been reported to 
date. 
 
PET imaging of glucose metabolism. Studies using PET to image glucose metabolism have 
demonstrated metabolic decreases in the parietal, temporal, cingulate and frontal cortices in PD-MCI 
and PDD156–158. PDD and DLB are characterized by similar patterns of glucose metabolic changes159. 
When PDD and AD were compared, however, patients with PDD showed greater metabolic reduction 
in the visual cortex and relative preservation of metabolism in the medial temporal cortex156,157,159. The 
use of more sophisticated PET analysis has allowed the identification of PD-related metabolic brain 
networks underlying cognitive dysfunction in PD, including smaller areas, detected at the single-voxel 
level, in the occipital, parietal and frontal cortices160. However, even with advanced methods, 
discrimination between PDD and DLB has been difficult in view of the aforementioned similarities in 
metabolic network patterns, with the exception that metabolic decrease in the anterior cingulate is 
greater in patients with DLB than in those with PDD161. 
 
Cholinergic PET molecular imaging. The cholinergic system has a key role in functional and structural 
remodelling of the cortical circuits that underlie cognitive processing162. Cholinergic PET imaging 
studies seem to be consistent with post-mortem evidence suggesting that loss of cholinergic function, 
in the forebrain, is associated with the manifestation of PDD38,163–165. PET molecular imaging of 
acetylcholinesterase (AChE) activity has indicated that cholinergic denervation of the cerebral cortex 
is an early phenomenon in the course of PD, and is more widespread and profound in patients with 
PDD38,163. AChE PET imaging studies have demonstrated mean cortical AChE loss of 20–30% in patients 
with PDD, compared with 11–13% in patients with PD38,164–166. In PDD, loss of cholinergic function is 
evident in the temporal, frontal and medial occipital cortices, and in the thalamus38,164,167. A similar 
pattern is seen in DLB153,167, and to a lesser extent in AD165; however, thalamic cholinergic denervation 
is not observed in AD167. Cholinergic PET might also be sensitive also to subclinical dementia. In PD 
patients without a diagnosis of cognitive impairment, lower cortical AChE PET activity was associated 
with reduced cognitive performance scores for attention, memory and executive functions162,165,168. A 
number of molecular targets related to the cholinergic system can be evaluated with PET, and further 
studies are needed to understand cholinergic system involvement in the development of cognitive 
impairment in PD. 
 
Amyloid-β and tau PET in PDD. PET imaging of Aβ plaques in vivo has demonstrated that most AD 
cases and a subset of DLB cases show increased cortical Aβ retention169. Aβ PET imaging (FIG. 1) 
indicates that cortical and striatal Aβ pathology is relatively infrequent (incidence 15–20%) in patients 
with PDD169–172, but is sometimes uncovered by histopathology at post mortem173. Compared with 
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cortical β-amyloidopathy alone, the combined presence of striatal and cortical Aβ plaques was 
associated with worse cognitive impairment in PD174. Aβ retention in patients with PD-MCI predicted 
an increased risk of future cognitive decline175. 
A recent tau PET study has shown increased signal in the inferior temporal gyrus and precuneus 
in patients with PPD, which was associated with heightened cognitive impairment. These findings 
suggest that tau cortical aggregates are present in patients with PDD, and that tau PET data could be 
a marker of cognitive impairment176. 
As regards future research, application of novel neuroimaging techniques, including molecular 
imaging of α-synuclein, and of mitochondrial and non-TSPO (translocator protein) neuroinflammatory 
targets, could enhance our understanding of the mechanisms underlying cognitive impairment in PD, 
and accelerate the development of novel therapeutics. 
 
Electrophysiology 
Several studies, using a range of EEG and cognitive measures, have reported associations between 
slowing of the EEG in PD and cognitive deficits. The findings include associations between executive 
dysfunction177 or Mini-Mental State Examination (MMSE) score178 and spectral ratio (the ratio of fast 
to slow activity), between performance deficits in attention, executive function and memory and 
increased delta power179 or decreased EEG median frequency180, and between clinical ratings of 
background EEG slowing and combined MMSE and clock drawing test scores181. An increase in low-
frequency (delta and theta) EEG spectral power distinguishes PDD from PD and AD182.  
Indices of EEG slowing are predictive of the transition to dementia at 5 years (HR 13)183. Peak 
frequency magnetoencephalogram (MEG) slowing is also predictive of the transition to dementia 
(hazard ratio 3.9 at 7 years)147; however, unlike EEG studies, greater MEG predictive power was found 
at higher, beta band frequencies (HR 5.2). Interestingly, combining MEG and cognitive markers 
improved the prognostic power over and above the single markers, with a very high hazard ratio 
(>27)147. A recent review of evoked potential studies in PD has suggested that a delayed (but not 
decreased-amplitude) P3b component in classic oddball tasks is a trait-like marker of PD cognitive 
impairment and dementia184. The review also noted that the mismatch negativity component of pre-
attentive deviance detection tasks might be reduced more in PDD than in AD or DLB184. 
 
Combination of biomarkers 
As described above, the mechanisms underlying cognitive decline in PD are heterogeneous and, thus, 
the various biomarker modes show different yet connected brain changes. Creation of multiple 
models, by combining different types of markers, may provide complementary information and 
improve the prognostic accuracy for cognitive decline in PD. CSF or blood-based markers can inform 
the biochemical changes underlying volume reductions identified in imaging studies, as shown with 
some success in AD185. 
Compta and colleagues reported interesting associations between structural imaging and CSF 
protein changes. In a cross-sectional study, high t-tau and p-tau and low Aβ42 values were associated 
with reduced grey matter volume in patients with PDD, but not in PD and non-PD controls186. Similar 
findings were reported by a different group187. In a subsequent longitudinal study, low CSF Aβ42 was 
associated with cortical thinning, and a combination of biomarker pathologies was a stronger predictor 
of cognitive decline and dementia than was a single biomarker pathology114. Finally, low CSF α-
synuclein was associated with frontal cortical thinning in PD patients without dementia and in a group 
with idiopathic RBD, whereas in patients with PDD, cortical atrophy was associated with increased total 
CSF α-synuclein and t-tau106.  
In two studies combining CSF biomarkers and SPECT striatal dopamine transporter uptake in 
early PD, reduced striatal uptake was associated with low CSF levels of t-tau and p-tau188 but not α-
synuclein189. In an fMRI study, activity in motor-related networks correlated with CSF total α-synuclein, 
indicating that α-synuclein contributes to motor-related resting state networks in PD. In PD patients 
without dementia, CSF α-synuclein was associated with the dorsal attentional network, suggesting that 
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α-synuclein is also involved in cognition. No associations between resting state fMRI networks and CSF 
Aβ were found190. 
Taken together, these studies support the hypothesis that the cognition-related volume loss 
in PD is related to three key pathologies: α-synuclein, tau and amyloid. This idea is consistent with 
post-mortem studies demonstrating that amyloid, tau and α-synuclein pathologies contribute to 
neuronal loss and cognitive decline from relatively early disease stages. 
 
Management 
Antidementia drugs for PDD 
Robust evidence is available to support the use of cholinesterase inhibitors to treat dementia in PD191. 
The best evidence came from the EXPRESS study of rivastigmine 192, and supportive data for donepezil 
were reported in the EDON study193. Memantine was tested in two medium-sized studies including 
both PDD and DLB cohorts194,195; only one of these studies found an effect in the PDD group194. Effect 
sizes were relatively small, for example, the difference in MMSE scores between patients treated with 
rivastigmine and placebo was 1.0 (REF. 192), with an SD of 3.8 in the treated group, indicating a Cohen’s 
d effect size between 0.25 and 0.30. A meta-analysis191 indicated that antidementia drugs did not 
increase mortality, and the drop-out rates did not differ between donepezil, rivastigmine, memantine 
and placebo groups. Compared with placebo, rivastigmine — but not donepezil or mementine — was 
associated with an increased incidence of adverse events. Preservation of frontoparietal and default 
mode cholinergic networks was recently reported to be associated with a positive response to 
cholinergic agents196, and might enable the identification of patients who are likely to benefit from this 
treatment. 
 
Potential treatments for PD-MCI 
As yet, no disease-modifying treatments with effects on cognition in PD are available, and there is no 
robust evidence that progression to dementia can be impeded. Epidemiological studies indicate that 
green tea and coffee can influence the risk of PD and, thus, a potential preventive role has been 
explored, although the effects on cognitive decline are unclear197,198. 
In the first trial in PD-MCI, rivastigmine patch offered some benefit, although the primary 
outcome measure — clinical impression of change — was not significantly affected199. However, 
significant effects were observed on one of the secondary outcomes, a scale measuring everyday 
cognitive activities. Of note, the study had a cross-over design, and included only 26 patients. Further 
studies of rivastigmine or other cholinesterase inhibitors for PD-MCI are warranted. 
Theoretical and preliminary empirical evidence supports the hypothesis that rasagiline, a 
selective monoamine oxidase B inhibitor with effects on motor symptoms in PD, also has a positive 
cognitive effect. In a relatively large, placebo-controlled, randomized trial over 24 weeks, however, 
rasagiline did not significantly improve cognitive functioning in patients with PD-MCI200. 
In a study focusing on depression, atomoxetine, a selective noradrenaline reuptake inhibitor, 
was associated with some cognitive benefit in patients with PD201. On a relatively insensitive screening 
instrument such as the MMSE, the placebo group worsened by 0.5 points whereas the atomoxetine 
group improved by 0.8 points, a statistically significant difference. Further support for the use of 
atomoxetine or other noradrenergic agents was provided in a single-dose, placebo-controlled study, 
which showed that 40 mg atomoxetine improved selected tests of decision-making and attention in 
PD202. We are not aware of any systematic studies of serotonergic agents in the context of cognition in 
PD, but vortioxetine, a novel agent that acts on a number of serotonergic receptors in addition to 
inhibiting serotonin reuptake, has produced cognitive improvement in elderly patients with 
depression203 and is a candidate for trials in PD. Various studies are ongoing, including trials of 5-HT6 
receptor antagonists and donepezil for PD-MCI. 5-HT6 receptor antagonists might exert effects on 
cognition and mood owing to enhancement of cholinergic, glutamatergic, noradrenergic and 
dopaminergic neurotransmission, and the SYNAPSE study is exploring the effects of these agents in 
PDD. 
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Disease-modifying agents that slow disease progression in PD, including delaying the onset of 
dementia, are an urgent unmet need. The most interesting approaches include passive and active 
immunotherapies targeting Aβ, tau and α-synuclein, which might be particularly relevant for diseases 
such as PD, which are characterized by accumulation and prion-like propagation of toxic protein 
aggregates204. Other potential strategies include drugs addressing mitochondrial dysfunction, anti-
inflammatory agents, GBA-active agents, stimulation of neurogenesis, and neurotrophic factors55. As 
amyloid pathology has a prominent role in dementia development in PD, strategies to reduce Aβ 
toxicity — for example, by influencing clusterin-associated pathways205 — might be relevant in this 
context. Interestingly, apomorphine, which is used to treat motor complications in PD, has been shown 
in animal studies to reduce Aβ accumulation and toxicity, possibly via antioxidative mechanisms206. In 
a recent post-mortem study, PD patients without dementia who had received apomorphine treatment 
showed reduced Aβ deposition compared with untreated patients207, and in a comparative open-label 
trial, apomorphine infusion was associated with improvement of several NMS208. Thus, placebo-
controlled clinical trials to test whether apomorphine can delay dementia onset in PD are warranted. 
 
Non-pharmacological approaches 
Cognitive training. Studies employing systematic cognitive training to improve cognition have been 
conducted in AD and, more recently, in PD. A review and meta-analysis209 based on seven studies 
involving 272 patients with PD (MMSE scores 27–29) showed small but statistically significant 
improvements in working memory, processing speed and executive functioning after cognitive 
training. Large multicentre studies are needed to confirm these encouraging findings. 
 
Physical exercise. Aerobic physical exercise has a range of beneficial effects on the brain, with potential 
relevance to cognition. A review based on seven studies concluded that physical exercise can improve 
motor sysmptoms and several NMS in PD210, possibly by improving perfusion, or by promoting growth 
hormone release or angiogenesis. In one relatively large study, 51 PD patients without dementia were 
randomly assigned to a progressive strengthening exercise training programme or to a simpler 
programme focusing on stretching, balance, breathing and non-progressive strengthening, 
administered twice a week for 24 months211. No differences between the groups were observed, 
although both groups showed evidence of improvement of attention and working memory after 24 
months. Larger studies with carefully designed control conditions are needed to test whether physical 
exercise can improve cognition in PD. 
 
Neurostimulation. Deep brain stimulation of the subthalamic nucleus is an established practice in PD. 
However, cognition might be adversely affected, not only postoperatively, with accelerated decline of 
executive functions being reported212. By contrast, there is some preliminary evidence of positive 
cognitive effects after stimulation of the cholinergic nucleus basalis of Meynert in patients with AD213. 
Given the probable contribution of cholinergic deficits to cognitive impairment in PD, this approach 
might be relevant in the PD context214, and studies are ongoing. 
 
Conclusions 
In addition to the well-known high risk of dementia in the later stages of PD, recent research has 
established the high frequencies of SCD and MCI as harbingers of dementia in PD. Cognitive 
impairment might occur very early in the disease course, even before the onset of motor symptoms in 
the prodromal state. A variety of mechanisms contributing to cognitive decline in PD are gradually 
being revealed; in addition to α-synuclein toxicity, the potential contributions of other pathologies, 
mitochondrial disturbances, inflammatory changes and genetic factors are currently under 
investigation. Related to these changes, a number of imaging, electrophysiological and CSF-based 
biomarkers have already been shown to be associated with cognitive impairment in PD, and studies 
consistently show that reduced CSF Aβ42 concentrations predict more rapid cognitive decline. 
However, following the demonstration of efficacy of a cholinesterase inhibitor for the treatment of 
PDD more than 10 years ago, no additional convincing evidence has emerged regarding the treatment 
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or prevention of PD-MCI and PDD. Therapies for PDD remain a key avenue for future investigations, 
and several promising candidates are now being explored. 
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additional criteria, including high-quality reviews, sample size and longitudinal follow-up. 
 
Key points 
 The full spectrum of cognitive impairment, from subjective cognitive decline to dementia 
[Au: OK?], has been observed in Parkinson disease (PD) 
 Mild cognitive impairment in PD [Au: OK?] usually progresses to dementia, but can be stable 
and even revert in some patients 
 The aetiology of cognitive impairment in PD has not been fully elucidated, but limbic and 
cortical Lewy body pathology seems to be the main cause 
 Amyloid plaque pathology also contributes to cognitive decline in PD [Au: OK?], and amyloid 
pathology detected by cerebrospinal fluid analysis and imaging can predict subsequent 
dementia 
 Other probable mechanisms include genetics, synaptic pathology, neurotransmitter changes 
and inflammation 
Commented [DÅ1]: yes 
Commented [DÅ2]: yes, selected one, including our 
own, how can we formulate this, 
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 Cholinesterase inhibitors have symptomatic effects, but no disease-modifying treatments are 
available to reduce the risk of dementia in PD 
 
Box 1 | Mechanisms of cognitive decline 
The following mechanisms are proposed to contribute to cognitive decline in Parkinson disease: 
 Protein misfolding (α-synuclein, amyloid and tau) 
 Neurotransmitter activity 
 Synaptic dysfunction and loss 
 Neuroinflammation and diabetes 
 Mitochondrial dysfunction and retrograde signalling 
 Microglial and astroglial changes 
 Genetics 
 Epigenetics 
 Adenosine receptor activation [Au: OK?] 
 Cerebral network disruption 
 
Box 2 | Potential genetic risk factors for cognitive impairment in PD [Au: I have reformatted this item 
as a box — we generally avoid two-column tables, unless there is no other alternative] 
GBA (glucosylceramidase) 
Mutations are associated with greater cognitive impairment and risk of dementia in patients with Parkinson disease (PD) [Au: 
OK?]72–77. 
MAPT (microtubule-associated protein tau) 
Mixed findings for cognitive impairment: the H1 haplotype is associated with an increased risk of dementia and [Au: OK?] 
modulation of temporal–parietal activation, as measured by functional MRI (fMRI)11,70,81,82,86,87,90,91. 
APOE (apolipoprotein E) 
The APOE*ε4 allele was associated with cognition in most (but not all) studies: evidence of distinct word list learning and 
semantic verbal fluency deficits; mixed evidence for dementia risk; associated with modulation of temporal–parietal 
activation, as measured by fMRI70,80–83,86,92.  
LRRK2 (leucine-rich repeat serine/threonine-protein kinase 2) 
No association in the majority of studies, but some larger studies reported a reduced prevalence of cognitive impairment and 
dementia in carriers of LRRK2 mutations [Au: changes OK?]57–65,93,94. 
SNCA (α-synuclein) 
One study found no association between the rs356219 polymorphism and cognition in sporadic PD, but multiplications and 
disease-causing mutations are associated with cognitive decline and dementia in monogenic PD66,67,70,95. 
COMT (catechol-O-methyltransferase) 
Mixed findings for cognition; some evidence that the Met allele is associated with impairment on frontal-dependent tasks; 
no evidence for dementia risk; associated with modulation of frontal networks6,9,73,81,82,86,96,97. 
BDNF (brain-derived neurotrophic factor) 
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Mixed findings: one of three studies reported an association between cognitive impairment and the Gly196Ala 
polymorphism98–100. 
UBQLN1 (ubiquilin-1) 
No association with cognitive impairment [Au: OK here and below?]101. 
FMR1 (fragile X mental retardation protein 1) 
No association with cognitive impairment102. 
Immune/inflammatory genes: IL10, IL17A, IUL-18 [Au: I can’t find any reference to this gene in the literature or the gene 
databases — please can you check that the name is correct?], IFNG 
Mixed findings: IL10 was associated with lower risk of cognitive impairment and IL17A was associated with greater risk in one 
study103, but not in a subsequent study104. 
 
Figure 1 | Amyloid-β PET scans in Parkinson disease dementia. Axial slices from two patients with 
Parkinson disease dementia, showing a | absence and b | presence of amyloid-β binding. 11C-PiB, 11C-
labelled Pittsburgh compound B. 
Figure 2 | Overview of risk factors for Parkinson disease dementia. Three different categories of risk 
factors for Parkinson disease dementia (PDD) — clinical, molecular, and structural/functional imaging 
— are illustrated. Factors with evidence from longitudinal studies are shaded red, and factors with 
evidence from cross-sectional studies are shaded grey [Au: changes to this sentence OK?]. 
Interrelationships between factor categories (bidirectional arrows) and temporal relationships 
between cross-sectional factors and PDD (unidirectional arrows) remain unclear. MCI, mild cognitive 
impairment; MEG, magnetoencephalogram. 
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Table 1 | Development of MCI and dementia from time of PD diagnosis: longitudinal studies 
Study N Duration 
(years) 
MCI at 
baseline 
(%) 
MCI at 
follow-
up (%) 
Dementia 
during 
study (%) 
Comments MCI and risk of 
dementia 
Refs 
Pigott, K. et al. (2015) 141 4.4 0 47.4* 28 Normal 
cognition at 
baseline 
– 8 
PARKWEST 
Pedersen, K. F. et al. 
(2013) 
182 5 20.3 – 19.2 – RR 39.2, 
P < 0.001 
5 
Amsterdam 
Broeders, M. et al. (2013) 
123 5 35 50‡ 13.8 – “All patients 
who progressed 
to PD dementia 
had MCI at a 
previous 
assessment” 
10 
PPMI 
Weintraub, D et al. 
(unpublished work) [Au: 
OK?]  
423 3 10 15–21§ 3–6§ – – – 
CamPaIGN 
Williams-Gray, C. H. et al. 
(2013) 
142 10 364 62 at 3 
years|| 
46 (17 at 
5years) 
– Reduced 
semantic 
fluency (HR 
3.05) and 
pentagon 
copying (HR 
[Au: OK?] 2.55) 
11 
DeNoPa 
Mollenhauer, B et al. 
(personal 
communication) [Au: OK? 
If this is not your own 
work, we require written 
consent from the original 
authors for inclusion of 
this information] 
118 2 26 27 18.6 – – – 
Napoli 
Santangelo, G. et al. 
(2015) 
76 4 32.9 38.2 5.4 50% MCI at 
4 years 
– 7 
NYPUM 
Domellöf, M. E. et al. 
(2015) 
147 5 42.6 – 27.6 – MCI at baseline 
6.5 x increased 
risk for 
dementia 
12 
Sydney 
Hely, M. A. et al. (2008) 
136 20 – – 83 MCI criteria 
not 
available at 
study start 
– 13 
*Any cognitive impairment. ‡Of those without dementia. §Using different criteria. ||Cognitive 
impairment rather than MCI. MCI, mild cognitive impairment; N, number of participants; PD, 
Parkinson disease. 
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Table 2 | Predictive effects of CSF markers on cognitive decline in PD: longitudinal studies 
Study N Baseline 
MMSE 
score 
Disease 
duration 
(years) 
Duration 
of 
follow-
up 
(years) 
CSF markers 
studied (in 
addition to total 
tau, 
phosphorylated 
tau and Aβ42) 
Outcome 
measures [Au: 
OK?] 
Results Refs 
Compta, Y. 
et al. 
27 28 10 1.5 – De—mentia Low Aβ42 
predicted 
dementia 
114 
Siderowf, 
A. et al. 
45 DRS 
score: 
133 
11 1.5 – DRS score Low Aβ42 
predicted 
more rapid 
decline on 
DRS 
113 
Parnetti, L. 
et al. 
44 27 3 3  α-Synuclein 
(total, oligomer) 
MMSE and 
Montreal 
Cognitive 
Assessment 
score 
Low Aβ42 
predicted 
more rapid 
decline 
115 
Alves, G. et 
al. 
104 28 De novo 5  – Dementia Low Aβ 
predicted 
early 
dementia 
111 
Bäckström, 
D. C. et al. 
99 29 1.4 5–9 α-Synuclein total, 
NFL, H-FABP 
Dementia Low Aβ42, NFL 
and H-FABP 
predicted 
dementia 
109 
Hall, S. et 
al. 
42 29 7 2 α-Synuclein total, 
NFL 
Dementia Low Aβ 
predicted 
memory 
decline, high 
α-synuclein 
predicted 
reduced 
cognitive 
speed 
110 
Terrelonge, 
M. et al. 
341 – 0.6 2 α-Synuclein total Four domains: 
memory, 
visuospatial, 
working 
memory–
executive 
function, [Au: 
OK, for 
consistency 
with the 
original paper?] 
and attention 
processing 
speed 
Low Aβ42 
predicted 
cognitive 
impairment at 
follow-up 
112 
Stewart, T. 
et al. 
403 28.9 2.1 1.8 α-Synuclein total Tests of verbal 
memory, 
cognitive 
Lower α-
synuclein 
predicted 
117 
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processing 
speed, and 
visuospatial 
working 
memory 
better 
preservation 
of cognitive 
function 
Aβ, amyloid-β; CSF, cerebrospinal fluid; DRS, Dementia Rating Scale; H-FABP, fatty acid-binding 
protein, heart; MMSE, Mini-Mental State Examination; N, number of participants; NFL, neurofilament 
light chain protein; PD, Parkinson disease. 
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